A5020378586- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Biosensors and Analytical Detection
- SARS-CoV-2 detection and testing
Rockefeller University
2021
The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic antibodies urgently demands powerful new therapeutics that can resist viral escape. We therefore generated a large nanobody repertoire to saturate the distinct highly conserved available epitope space spike, including S1 receptor binding domain, N-terminal S2 subunit, identify sites may reflect novel mechanisms neutralization. Structural mapping functional assays show indeed these stable monovalent nanobodies...
SUMMARY Despite the great promise of vaccines, COVID-19 pandemic is ongoing and future serious outbreaks are highly likely, so that multi-pronged containment strategies will be required for many years. Nanobodies smallest naturally occurring single domain antigen binding proteins identified to date, possessing numerous properties advantageous their production use. We present a large repertoire high affinity nanobodies against SARS-CoV-2 Spike protein with excellent kinetic viral...